Selexipag Tablet, Film Coated
Product Images NDC 70710-1557

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Selexipag (NDC 70710-1557). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals (usa) Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 01)

Chemical structure of selexipag, depicting its molecular framework with characteristic rings and functional groups as part of the active ingredient representation.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 02)

A chart showing the fold-change in drug exposure (AUC and Cmax) for Selexipag and its active metabolite when co-administered with various interacting drugs. The x-axis displays fold-change on a logarithmic scale, comparing values relative to Selexipag alone. Interacting drugs listed include gemfibrozil, clopidogrel, lopinavir/ritonavir, rifampin, warfarin, and PDE-5 inhibitors, each with corresponding fold-change points and 90% confidence intervals.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 03)

A chart depicting the fold-change in pharmacokinetic parameters AUC and Cmax of R-warfarin, S-warfarin, midazolam, and 1OH-midazolam when co-administered with Selexipag compared to each drug alone. The graph shows point estimates and 90% confidence intervals for these interactions.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 04)

A Kaplan-Meier survival curve comparing the percentage of event-free patients over 36 months between Selexipag and placebo groups. The graph displays two lines: a solid line for Selexipag and a dashed line for placebo, showing higher event-free survival for Selexipag. Below the x-axis, numbers of patients at risk at various time points are listed for both groups. Statistical data including hazard ratio, confidence interval, and p-value are also included.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 05)

A cumulative probability curve comparing Selexipag versus placebo over 36 months. The y-axis shows estimated cumulative probability in percent, while the x-axis represents months from randomization. The chart includes patient count tables at risk for both Selexipag and placebo groups at multiple time points.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 06)

A line graph comparing the estimated cumulative probability (%) over months from randomization (up to 36 months) for Selexipag patients versus placebo patients. Selexipag shows a lower cumulative probability curve than placebo. The number of patients at risk for each group is listed below the x-axis at various time points.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 07)

Kaplan-Meier curve illustrating the estimated cumulative probability percentage over 36 months from randomization, comparing Selexipag patients to placebo patients. The x-axis shows months from randomization, and the y-axis shows estimated cumulative probability percentage. Patient numbers at risk at various months for both groups are included below the graph.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 08)

A forest plot chart showing hazard ratios and 95% confidence intervals for various subgroups comparing Selexipag to placebo. Subgroups include overall treatment effect, PAH therapy status, WHO functional class, sex, race, age, PAH etiology, and geographic region. The chart visually represents favoring Selexipag or placebo with data points, confidence intervals, and numerical hazard ratios.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 09)

Selexipag Tablets 200 mcg film-coated oral tablets packaging label. The label indicates a container of 60 tablets by Zydus Pharmaceuticals (USA) Inc. Storage and handling instructions are included, with emphasis on child-resistant packaging and prescription-only status.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 10)

Label for Selexipag Tablets 400 mcg film-coated oral tablets, packaged as 60 tablets per container. The label includes the NDC number 70710-1552-6 and states the product is Rx only. It also provides manufacturer and distributor information for Zydus Lifesciences Ltd. and Zydus Pharmaceuticals (USA) Inc., respectively, along with storage instructions and child-resistant packaging notice.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 11)

Selexipag Tablets 600 mcg film-coated tablets label with NDC 70710-1553-6 from Zydus Pharmaceuticals (USA) Inc. The label indicates 60 tablets per container, prescription only, with storage instructions and child-resistant packaging details. Manufacturer information is listed as Zydus Lifesciences Ltd., India.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 12)

Label for Selexipag Tablets 800 mcg film-coated oral tablets by Zydus Pharmaceuticals (USA) Inc. The package contains 60 tablets for prescription use. The label includes storage instructions, prescribing information notes, a barcode, and manufacturer details.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 13)

Selexipag Tablets 1,000 mcg film-coated tablets label showing NDC 70710-1555-6. The label includes product name, strength, dosage form, package count of 60 tablets, and Rx only designation. Manufacturer is Zydus Lifesciences Ltd, India, distributed by Zydus Pharmaceuticals (USA) Inc. Storage and safety instructions are also present.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 14)

Selexipag Tablets 1,200 mcg film-coated oral tablets label showing the product name and strength prominently. The label includes storage instructions, dosage information, and child-resistant packaging warning. It states the package contains 60 tablets, is RX only, and is manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals (USA) Inc. The NDC number is 70710-1556-6.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 15)

Label for Selexipag Tablets 1400 mcg, oral film-coated tablets, manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals (USA) Inc. The label includes dosage strength, prescription status, storage instructions, child-resistant packaging notice, and warnings to keep out of reach of children. The package contains 60 tablets.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 16)

Label for Selexipag Tablets 1,600 mcg oral film-coated tablets by Zydus Pharmaceuticals (USA) Inc. The label states a package size of 60 tablets with Rx only. It includes storage instructions, child-resistant packaging notice, manufacturer and distributor information, and a barcode. NDC 70710-1558-6 appears at the top.*

FDA Label Image

Image (E5ee2298 Ac53 4e02 8e3e 64c33b525d7f 17)

The carton label for Selexipag Tablets, film-coated oral tablets available in two strengths: 200 mcg (140 count) and 800 mcg (60 count). The label indicates it is a titration pack by Zydus Pharmaceuticals (USA) Inc., featuring distinct color backgrounds for each strength and includes manufacturing and storage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.